** Shares of Orthocell OCC.AX rise 14.3% to A$1.435, set for strongest session since January 22, if gains hold
** The biotech firm applies for a regulatory approval to begin sales of its nerve repair product Remplir in Hong Kong
** Co expects to receive approval by Q4 CY2025
** About 2.1 million shares change hands, 1.4x times the 30-day average of 1.5 million
** Stock up 5.2% YTD, including moves in current session
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。